Research analysts at Bank of America assumed coverage on shares of Merck & Company, Inc. (NYSE:MRK) in a research note issued to investors on Tuesday. The firm set a “buy” rating and a $64.00 price target on the stock. Bank of America’s price objective points to a potential upside of 15.61% from the company’s current price.

Several other equities research analysts also recently issued reports on MRK. BidaskClub downgraded shares of Merck & Company, Inc. from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. BMO Capital Markets reiterated a “buy” rating and issued a $72.00 target price on shares of Merck & Company, Inc. in a research note on Friday, September 8th. Morgan Stanley downgraded shares of Merck & Company, Inc. from an “overweight” rating to an “equal weight” rating and set a $56.00 target price for the company. in a research note on Monday, October 30th. Credit Suisse Group reiterated an “outperform” rating and issued a $74.00 target price (down from $75.00) on shares of Merck & Company, Inc. in a research note on Tuesday, September 5th. Finally, UBS cut their target price on shares of Merck & Company, Inc. from $72.00 to $67.00 and set a “buy” rating for the company in a research note on Monday, October 30th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $66.29.

Merck & Company, Inc. (MRK) opened at $55.36 on Tuesday. The firm has a market capitalization of $149,653.33, a PE ratio of 14.12, a PEG ratio of 2.54 and a beta of 0.78. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.57. Merck & Company, Inc. has a 1-year low of $53.63 and a 1-year high of $66.80.

Merck & Company, Inc. (NYSE:MRK) last announced its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.08. The company had revenue of $10.33 billion during the quarter, compared to analysts’ expectations of $10.54 billion. Merck & Company, Inc. had a return on equity of 27.08% and a net margin of 11.60%. Merck & Company, Inc.’s revenue for the quarter was down 2.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.07 EPS. sell-side analysts expect that Merck & Company, Inc. will post 3.95 earnings per share for the current fiscal year.

In other Merck & Company, Inc. news, Director Thomas H. Glocer sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total transaction of $281,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.25% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. Northeast Financial Consultants Inc bought a new position in shares of Merck & Company, Inc. during the first quarter worth approximately $222,000. Oxbow Advisors LLC increased its holdings in shares of Merck & Company, Inc. by 18.8% during the first quarter. Oxbow Advisors LLC now owns 11,495 shares of the company’s stock worth $730,000 after purchasing an additional 1,820 shares during the period. Rockefeller Financial Services Inc. increased its holdings in shares of Merck & Company, Inc. by 0.3% during the first quarter. Rockefeller Financial Services Inc. now owns 504,510 shares of the company’s stock worth $32,057,000 after purchasing an additional 1,429 shares during the period. Linscomb & Williams Inc. increased its holdings in shares of Merck & Company, Inc. by 8.5% during the first quarter. Linscomb & Williams Inc. now owns 71,518 shares of the company’s stock worth $4,544,000 after purchasing an additional 5,580 shares during the period. Finally, Canada Pension Plan Investment Board increased its holdings in shares of Merck & Company, Inc. by 70.4% during the first quarter. Canada Pension Plan Investment Board now owns 5,568,791 shares of the company’s stock worth $353,841,000 after purchasing an additional 2,300,200 shares during the period. Hedge funds and other institutional investors own 73.85% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Merck & Company, Inc. (MRK) Now Covered by Bank of America” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/11/30/merck-company-inc-mrk-now-covered-by-bank-of-america.html.

Merck & Company, Inc. Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & Company, Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.